Cell And Gene Therapy Manufacturing

  1. Why Clinical Requirements Change: Dr. Peter Marks on Pre-IND Meeting Pathways 1/30/2024

    Learn how clinical requirements change after the FDA and a company agree on a pathway during a pre-IND meeting and how the company might recover as a result.

  2. Innovative Contamination Control: Enabling Integrity And Efficiency 10/15/2024

    An integrated approach can enhance contamination control, boost process efficiency, and ensure the production of high-quality cell therapy products.

  3. Supply Chain And Operational Challenges Facing mRNA 1/29/2024

    Explore some of the biggest supply chain challenges facing mRNA cancer therapeutics and what short-term solutions may exist, starting with Chain of Custody/Chain of Identity.

  4. How Past Gene Therapy Approvals Are Shaping the Future with Dr. Peter Marks 1/30/2024

    In this segment of Cell & Gene Live, Dr. Peter Marks shared what he and his team have learned from current gene therapy approvals to accelerate future approvals.

  5. Unlocking The Future Of Allogeneic Cell Therapy For Oncology | Audience Q&A 5/6/2024

    Expert panelists in this Cell & Gene Therapy Live presentation provided detailed responses to questions about the potential risks of CAR-T therapy, screening criteria for donor material, comparability, and more.

  6. Major Advancements In mRNA 1/29/2024

    Experts on this Cell & Gene live event discuss the major scientific biological advances in understanding the potential for mRNA-based immunotherapies vaccines for cancer over the last 2 years.

  7. Thermo Fisher Scientific Single-Use Global Manufacturing Network 4/18/2022

    We have implemented a multi-tier strategy to improve the resiliency of our supply chain and created the largest networked single-use manufacturing organization in the world.

  8. Thermo Fisher Scientific Large Volume Liquid Expansion 5/2/2024

    Take an insightful look into the expansion of the large volume liquids manufacturing site at the Grand Island facility, highlighting the various stages of the manufacturing process and the capabilities it offers to support the bioprocessing industry.

  9. An Active Release Mechanism For Magnetic Separation And Cell Isolation 11/13/2023

    Discover an innovative active release solution that will serve autologous and allogeneic processes to the benefit of cell therapy patients.

  10. Considerations For Affinity Capture In An AAV Platform Downstream Process 6/2/2025

    This presentation explores the considerations when evaluating a platform affinity capture step for the purification of AAV vectors. Specificity, binding capacity, purity, yield, scalability and reusability are parameters that will be addressed.